Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | NQO1 | P15559 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227262 | 1.00 | NCF1 (0.56) | NCF1NQO1KDM4EALDH1A1GFER | |
| SCHEMBL11517853 | 0.91 | KDM4E (0.52) | NCF1NQO1KDM4EALDH1A1MAPT | |
| SCHEMBL12068392 | 0.91 | ALDH1A1 (0.57) | NCF1NQO1KDM4EALDH1A1GFER | |
| SCHEMBL31414248 | 0.84 | KDM4E (0.63) | NCF1NQO1KDM4EALDH1A1MAPT | |
| SCHEMBL11442590 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1GFERMAPTKMT2A | |
| SCHEMBL18809011 | 0.81 | NCF1 (0.57) | NCF1NQO1KDM4EALDH1A1MAPT | |
| SCHEMBL12068387 | 0.80 | NCF1 (0.56) | NCF1NQO1KDM4EALDH1A1KMT2A | |
| SCHEMBL3364517 | 0.80 | NCF1 (0.65) | NCF1NQO1KDM4EALDH1A1KMT2A | |
| SCHEMBL7694434 | 0.80 | CYP2A6 (0.60) | NCF1KDM4ERAB9ACYP1A2CYP2A6 | |
| SCHEMBL12068383 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1MAPTNQO2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| WO-2023225631-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-3484908-A1 | NON-NUCLEOSIDIC SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | AM Chemicals Llc (US) | 2019-05-22 | — | — | EP | claimed |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2018-01-18 | — | — | US | claimed |
| WO-2018013999-A1 | NON-NUCLEOSIDIC SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | AM CHEMICALS LLC (US) | 2018-01-18 | — | — | WO | claimed |
| US-20090307805-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V | 2009-12-10 | — | — | US | claimed |
| EP-1974053-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | Keygene N.V. (NL) | 2008-10-01 | — | — | EP | claimed |
| WO-2007073149-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V. (NL) | 2007-06-28 | — | — | WO | claimed |
| WO-2007073154-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V. (NL) | 2007-06-28 | — | — | WO | claimed |
| EP-0163316-B1 | PLATINUM-INTERCALATIVE COMPLEXES FOR THE TREATMENT OF CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-16 | — | — | EP | claimed |
| EP-0163316-A1 | Platinum-intercalative complexes for the treatment of cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1985-12-04 | — | — | EP | claimed |
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4525855-A1 | INTERCALATING SUGAR MOLECULES | Xalud Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20230407316-A1 | COMPOSITIONS AND METHODS FOR HIGH FIDELITY ASSEMBLY OF NUCLEIC ACIDS | GEN9, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023225631-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-1993020074-A1 | HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR ACRIDINE-9-CARBOXYLIC ACIDS | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0240914-B1 | PEPTIDE DERIVATIVES AND ACTIVITY MEASURING METHOD OF PHYSIOLOGICALLY ACTIVE SUBSTANCES USING THE SAME AS SUBSTRATES | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0163316-B1 | PLATINUM-INTERCALATIVE COMPLEXES FOR THE TREATMENT OF CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-16 | — | — | EP | disclosed |
| US-4843161-A | Platinum-intercalative complexes for the treatment of cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-06-27 | — | — | US | disclosed |
| EP-0163316-A1 | Platinum-intercalative complexes for the treatment of cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | SLC2A1, SLC2A2, SLC2A4 | NCF1 1569/4885NQO1 914/4885KDM4E 3652/4885 |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | NCF1 586/4885NQO1 2753/4885KDM4E 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.